Vu Mai, MD
Family Medicine · Marrero, LANPI 1497086755
Payments from drug & device makers
Across 540 payments — averaging $16.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Lilly USA, LLC$1K
- GSK$887
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$625
- AstraZeneca$492
- Bayer$411
- plus $3K from 28 others
What the payments were for
- Food & beverage$8,731100%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 170 | $2,156 |
| Lilly USA, LLC | 58 | $1,129 |
| GSK | 49 | $887 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 43 | $625 |
| AstraZeneca | 21 | $492 |
| Bayer | 25 | $411 |
| Novo Nordisk | 23 | $387 |
| Pfizer | 31 | $311 |
| Gilead | 17 | $299 |
| Astellas Pharma US Inc | 11 | $227 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 12 | $224 |
| Amgen | 11 | $206 |
| Boehringer Ingelheim | 11 | $186 |
| Axsome Therapeutics, Inc. | 6 | $125 |
| MDD US Operations, LLC | 1 | $113 |
| Vanda Pharmaceuticals Inc. | 5 | $110 |
| Scilex Pharmaceuticals Inc. | 5 | $101 |
| Orexo US, Inc. | 6 | $92 |
| Novartis | 5 | $87 |
| Exact Sciences | 4 | $78 |
| Otsuka America Pharmaceutical, Inc. | 4 | $69 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $65 |
| Kowa Pharmaceuticals America, Inc. | 3 | $64 |
| Corcept Therapeutics | 3 | $59 |
| Ardelyx, Inc. | 2 | $45 |
| Phathom Pharmaceuticals, Inc. | 2 | $37 |
| Biohaven Pharmaceuticals, Inc. | 2 | $35 |
| Abbott | 1 | $25 |
| Azurity Pharmaceuticals, Inc. | 1 | $23 |
| Braeburn Inc. | 1 | $17 |
| Lundbeck LLC | 1 | $17 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
| Genentech USA, Inc. | 1 | $15 |
| Aimmune Therapeutics, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$125
- Lucemyra/Lofexidine$113
How this compares
$8,745 in reported general payments places this provider in the 90th percentile of 1,469 family medicine providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 206 | $227,631 |
| FarxigaDapagliflozin Propanediol | 67 | $91,258 |
| OzempicSemaglutide | 72 | $81,506 |
| MounjaroTirzepatide | 63 | $75,089 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 105 | $69,588 |
| LinzessLinaclotide | 78 | $60,348 |
| UbrelvyUbrogepant | 11 | $39,822 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 237 | $39,082 |
| VraylarCariprazine Hcl | 23 | $35,400 |
| KerendiaFinerenone | 36 | $30,593 |
| JardianceEmpagliflozin | 26 | $30,486 |
| EliquisApixaban | 22 | $26,122 |
| TradjentaLinagliptin | 22 | $24,240 |
| JanuviaSitagliptin Phosphate | 15 | $23,886 |
| VemlidyTenofovir Alafenamide | 13 | $21,186 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $1,129 | $302,719269 claims |
| AbbVieLinzess, Ubrelvy, Vraylar, Restasis | $2,156 | $149,208127 claims |
| AstraZenecaFarxiga | $492 | $91,25867 claims |
| Novo NordiskOzempic | $387 | $81,50672 claims |
| GSKTrelegy Ellipta, Shingrix | $887 | $76,016136 claims |
| Boehringer IngelheimJardiance, Tradjenta | $186 | $54,72648 claims |
| BayerKerendia | $411 | $30,59336 claims |
| PfizerEliquis | $311 | $26,12222 claims |
| GileadVemlidy | $299 | $21,18613 claims |
| NovartisEntresto | $87 | $16,76524 claims |
| Orexo US, Inc.Zubsolv | $92 | $7,48713 claims |
| Aimmune Therapeutics, Inc.Zenpep | $14 | $4,91911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,469 family medicine providers in Louisiana.
Other family medicine in Marrero
- Brigetta YancyMarrero$16K
- Clinton GuilloryMonroe$18.5M
- Jason MorrisLake Charles$18M
- Michael SeepLake Charles$9.1M
- William NaboursLake Charles$3M
- Ramon VargasKenner$2.1M
- Stephen JonesNew Orleans$513K
- Joshua WhatleyLake Charles$366K
- Richard JeansonneMandeville$362K
- Kristen ThomasNew Orleans$361K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.